83 results
8-K
EX-99.2
MIRM
Mirum Pharmaceuticals Inc
8 Jan 24
Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates
8:30am
in direct markets Strong adherence & persistence Payor Acceptance: Reimbursement95% International Expansion: Multiple launches expected in 2024
424B5
r6rhgygzo8z0l097
2 Nov 23
Prospectus supplement for primary offering
4:59pm
8-K/A
EX-99.4
tvlyg
2 Nov 23
Financial Statements and Exhibits
4:05pm
8-K/A
EX-99.3
no66w
2 Nov 23
Financial Statements and Exhibits
4:05pm
S-3ASR
cq6qjf7yz4bs
13 Oct 23
Automatic shelf registration
4:47pm
8-K
EX-99.1
g7slqz
13 Oct 23
Other Events
4:16pm
8-K
EX-10.1
zklbq r56m4rr5k
30 Aug 23
Departure of Directors or Certain Officers
4:15pm
8-K
EX-2.1
5278s
17 Jul 23
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
8:16am
8-K
EX-99.2
ufge0by5
17 Jul 23
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
8:16am
S-3ASR
pc9l2c5s9
9 Sep 22
Automatic shelf registration
4:31pm
S-3ASR
EX-4.3
mdrld
9 Sep 22
Automatic shelf registration
4:31pm